Statistics in Medicine 2001-02-28

Sample size calculations for the two-sample problem using the multiplicative intensity model.

M V Bernardo, D P Harrington

Index: Stat. Med. 20(4) , 557-79, (2001)

Full Text: HTML

Abstract

In this paper we propose formulae for calculating the expected number of events or, alternatively, the required trial duration, for clinical trials involving two treatment groups in which patients may potentially experience multiple events and the data will be analysed using a multiplicative intensity (MI) model. We use a partial likelihood-based approach and examine in detail two MI models: one that includes a binary treatment variable as the only covariate and a three-state Markov process model in which a binary time-varying covariate is added to the previous model. For the simpler model, our formula coincides with those derived by Cook using full likelihood methods. We present applications of the derived formulae to chronic granulomatous disease and breast cancer data sets.Copyright 2001 John Wiley & Sons, Ltd.

Related Compounds

  • Fluoxymesterone

Related Articles:

Rat liver lysosomal and mitochondrial activities are modified by anabolic-androgenic steroids.

1999-02-01

[Med. Sci Sports Exerc. 31 , 243, (1999)]

Biotransformation of 17-alkyl steroids in the equine: high-performance liquid chromatography-mass spectrometric and gas chromatography-mass spectrometric analysis of fluoxymesterone metabolites in urine samples.

1997-12-19

[J. Chromatogr. B. Biomed. Sci. Appl. 704 , 119, (1997)]

Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.

2000-01-01

[J. Clin. Oncol. 18(2) , 262-6, (2000)]

Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures.

1995-08-01

[J. Pharmacol. Toxicol. Methods 33(4) , 187-95, (1995)]

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.

2006-07-01

[Breast Cancer Res. Treat. 98(2) , 217-22, (2006)]

More Articles...